[go: up one dir, main page]

FI963004L - Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita - Google Patents

Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita Download PDF

Info

Publication number
FI963004L
FI963004L FI963004A FI963004A FI963004L FI 963004 L FI963004 L FI 963004L FI 963004 A FI963004 A FI 963004A FI 963004 A FI963004 A FI 963004A FI 963004 L FI963004 L FI 963004L
Authority
FI
Finland
Prior art keywords
monoclonal antibodies
antibody formation
stimulate antibody
stimulate
formation
Prior art date
Application number
FI963004A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI963004A0 (fi
FI963004A7 (fi
Inventor
Britta Hardy
Avraham Novogrodsky
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of FI963004A0 publication Critical patent/FI963004A0/fi
Publication of FI963004A7 publication Critical patent/FI963004A7/fi
Publication of FI963004L publication Critical patent/FI963004L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)
FI963004A 1994-01-31 1995-01-30 Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita FI963004L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
PCT/US1995/001137 WO1995020605A1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies

Publications (3)

Publication Number Publication Date
FI963004A0 FI963004A0 (fi) 1996-07-29
FI963004A7 FI963004A7 (fi) 1996-09-27
FI963004L true FI963004L (fi) 1996-09-27

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963004A FI963004L (fi) 1994-01-31 1995-01-30 Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita

Country Status (20)

Country Link
US (1) US5897862A (lt)
EP (1) EP0742795B1 (lt)
JP (1) JP3478398B2 (lt)
CN (1) CN1052733C (lt)
AT (1) ATE171461T1 (lt)
AU (1) AU693526B2 (lt)
CA (1) CA2182289C (lt)
DE (1) DE69504955T2 (lt)
DK (1) DK0742795T3 (lt)
EE (1) EE03285B1 (lt)
ES (1) ES2124533T3 (lt)
FI (1) FI963004L (lt)
IL (1) IL108501A (lt)
LT (1) LT4225B (lt)
LV (1) LV11624B (lt)
MD (1) MD1374G2 (lt)
MX (1) MX9603080A (lt)
NO (1) NO317020B1 (lt)
RU (1) RU2155190C2 (lt)
WO (1) WO1995020605A1 (lt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145634C1 (ru) * 1998-03-12 2000-02-20 Булычева Татьяна Ивановна Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
RU2404993C2 (ru) * 2003-07-02 2010-11-27 Иннейт Фарма Композиции и способы регуляции клеточной активности nk
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
EP2439273B1 (en) * 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
PT2170959E (pt) * 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
ES2639857T3 (es) * 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
EP2734551B1 (en) 2011-07-24 2018-01-10 Cure Tech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CR20200423A (es) 2015-07-30 2021-01-20 Macrogenics Inc Moléculas de unión a pd-1 y métodos de uso de las mismas (divisional 2018-0062)
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
HK1251158A1 (zh) 2015-09-29 2019-01-25 细胞基因公司 Pd-1结合蛋白及其使用方法
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
KR20250140097A (ko) 2023-01-30 2025-09-24 키맵 리미티드 항체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
FI963004A0 (fi) 1996-07-29
CA2182289C (en) 2003-10-21
EP0742795B1 (en) 1998-09-23
JP3478398B2 (ja) 2003-12-15
ES2124533T3 (es) 1999-02-01
LV11624A (en) 1996-12-20
MD1374F2 (en) 1999-12-31
AU693526B2 (en) 1998-07-02
NO963168D0 (no) 1996-07-29
IL108501A0 (en) 1994-05-30
MD1374G2 (ro) 2000-09-30
CN1052733C (zh) 2000-05-24
US5897862A (en) 1999-04-27
JPH09508390A (ja) 1997-08-26
EE03285B1 (et) 2000-08-15
FI963004A7 (fi) 1996-09-27
LT4225B (en) 1997-10-27
RU2155190C2 (ru) 2000-08-27
LT96115A (en) 1997-05-26
AU1868695A (en) 1995-08-15
DK0742795T3 (da) 1999-06-14
WO1995020605A1 (en) 1995-08-03
NO963168L (no) 1996-09-27
CA2182289A1 (en) 1995-08-03
IL108501A (en) 1998-10-30
LV11624B (en) 1997-06-20
DE69504955D1 (de) 1998-10-29
NO317020B1 (no) 2004-07-26
MX9603080A (es) 1998-01-31
EP0742795A1 (en) 1996-11-20
CN1145077A (zh) 1997-03-12
ATE171461T1 (de) 1998-10-15
DE69504955T2 (de) 1999-05-27

Similar Documents

Publication Publication Date Title
FI963004L (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
PT719859E (pt) Anticorpo monoclonal anti-alfa v-integrina
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DE69920897D1 (de) Monoklonale antikörper mit verringerter immunisierungsfähigkeit
DK666389D0 (da) Monoklonalt antistof
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
FI964845A7 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
DE69232604D1 (de) Antikörperkonstrukte
DE69530078D1 (de) Antigen/antikörper spezifitätsaustauscher
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
FI945865A7 (fi) Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita
DE69738312D1 (de) Hepatitis b monoklonale antikörper
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
NO981272D0 (no) Humanisert anti-human-Fas-antistoff
NO20004251D0 (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
DK717888A (da) Monoklonale antistoffer
FI934963A7 (fi) CTAA 81AV78, monoklonaalisen 81AV78-humaanivasta-aineen tunnistama ant igeeni
NO890116D0 (no) Monoklonale antistoffer.
GB9718911D0 (en) Monoclonal antibodies
DK474189A (da) Monoklonalt antistof
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
GB9721432D0 (en) Improved production of antibodies through the use of antigen antibody complexes
DE69023717D1 (de) Monoklonaler Antikörper.
DK413389A (da) Monoklonale antistoffer
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.